Abiopharma

🔍 Rogers Douglas G (Executive)

Company: Atlas Energy Solutions Inc. (AESI)

Report Date: 2026-03-13

Detailed Transactions and Holdings:

• Acquired 12,536 shares of Common Stock (Direct)
  Date: 2026-03-13 | Code: M | equity_swap_involved: false | shares_owned_after: 22,736.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 12,536 shares of Common Stock (Direct)
  Date: 2026-03-18 | Code: J | equity_swap_involved: false | shares_owned_after: 10,000.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 12,536 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-13 | Code: M | equity_swap_involved: false | shares_owned_after: 22,200.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5, F6

Footnotes:

• F1: Consists of shares of common stock, par value $0.01 per share ("Common Stock"), of Atlas Energy Solutions Inc. ("Atlas") issued upon the vesting of 12,536 Restricted Stock Units ("RSUs") awarded to the Reporting Person on March 13, 2025 pursuant to the Atlas Energy Solutions Inc. 2023 Long Term Incentive Plan (the "Plan").
• F2: The Reporting Person serves as Executive Director of The Sealy & Smith Foundation, a charitable foundation (the "Foundation"). The Foundation and the Reporting Person have entered into an Outside Compensation Agreement dated as of November 15, 2023 (the "Agreement"), which requires that all compensation received by the Reporting Person from Atlas in connection with the Reporting Person's service as a director of Atlas be transferred to the Foundation. Under the Agreement, equity awards granted to the Reporting Person subject to vesting conditions are required to be transferred, for no consideration, to the Foundation upon vesting and are held by the Reporting Person for the benefit of the Foundation until the transfer to the Foundation is complete.
• F3: Includes 12,536 shares of Common Stock that are required to be transferred to the Foundation in accordance with the terms of the Agreement.
• F4: Each RSU represents the contingent right to receive one share of Common Stock.
• F5: On March 13, 2025, the Reporting Person was granted an award of 12,536 RSUs, vesting in full on the first anniversary of the grant date, subject to continued service through the vesting date, and unless accelerated vesting of a particular award is authorized by the Committee (as defined in the Plan) .
• F6: The Reporting Person disclaims beneficial ownership of the shares of Common Stock underlying the RSUs except to the extent of his pecuniary interest therein, if any. Pursuant to the Agreement, upon the vesting of such RSUs, the Reporting Person will be required to transfer the underlying shares of Common Stock to the Foundation for no consideration.